Cost Plus Drugs deploys AI-driven modular manufacturing pods

Cost Plus Drugs, which launched in January 2022 with 111 generic medications, has expanded its catalog to approximately 4,000 SKUs. The company is leveraging AI and robotics to shrink drug manufacturing facilities from football-field-sized areas to 5,000 square feet, allowing for four-hour production turns. This technology enables the creation of 'pods' the size of a tractor trailer, costing approximately $20 million each, which can be shipped to research hospitals or disaster zones, including FEMA deployments, to manufacture sterile injectables, tablets, or N-of-1 personalized therapies.

The company projects selling a few hundred pods per year within two years and a few thousand per year within five years. It plans to mark up products at 10-12% on its marketplace and 15% on retail drugs. A major barrier to scaling generic manufacturing is the cost of Abbreviated New Drug Application filings, which cost $365,000 each plus fees, totaling $365 million for 1,000 drugs. Cuban views trust and transparency as the core product, aiming to disrupt healthcare by making manufacturing and pricing fully visible and affordable.